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The CRASH-2 trial is a World Health Organization
(WHO) supported large international multi-centre
randomized placebo controlled trial of the effects of
the antifibrinolytic agent tranexamic acid on death and
transfusion requirements in adult trauma patients with
significant haemorrhage. The trial aims to recruit 20,000
patients worldwide. This article gives the rationale for
the trial, an update on its progress and is an invitation
to doctors in India to join CRASH-2 trial.
Between the ages of 5 to 45 yr, trauma is second
only to HIV/AIDS as a cause of death. Worldwide
over three million people die every year as a result
of trauma, many after reaching hospital1. It is well
documented that funding for trauma research is less
than almost any other cause of human suffering. A
WHO study compared the level of research funding
with current and projected (2020) disease burden. The
results showed clearly the relative under-funding of
research on injuries. A more recent study from the
UK shows that injury remains the most under-funded
of all health issues2,3. Trauma is a major public health
problem in India, particularly given the increasing
number of road traffic crashes.
Among trauma patients who do survive to reach
hospital, exsanguination is a common cause of death,
accounting for nearly half of in-hospital trauma
deaths4. Central nervous system injury and multi-
organ failure account for most of the remainder, both
of which can be exacerbated by severe bleeding5.
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The haemostatic system mounts a similar
response to maintain the integrity of the circulatory
system after severe vascular injury, whether the cause
is traumatic or surgical6. Any consequent massive
blood loss presents an extreme challenge to the
coagulation system. Part of the response to surgery
and trauma, in any patient, is stimulation of
fibrinolysis (clot breakdown) which may become
pathological (hyper-fibrinolysis) in some6.
Antifibrinolytic agents have been shown to reduce
blood loss in patients with both normal and
exaggerated fibrinolytic responses to surgery, and do
so without apparently increasing the risk of
post-operative complications. Moreover, there
is no apparent increased risk of venous
thromboembolism7.
Systemic antifibrinolytic agents are widely used
in major surgery to reduce surgical blood loss. A
systematic review8 of randomized controlled trials of
antifibrinolytic agents (mainly aprotinin or tranexamic
acid) in elective surgical patients identified 89 trials
including 8,580 randomized patients (74 trials in
cardiac, eight in orthopaedic, four in liver, and three
in vascular surgery). The results showed that these
treatments reduced the numbers needing transfusion
by one third, reduced the volume needed per
transfusion by one unit, and halved the need for further
surgery to control bleeding. These differences were
all highly statistically significant. There was also a
statistically non significant reduction in the risk of
death (RR=0.85: 95% CI 0.63 to 1.14) in the
antifibrinolytic treated group.
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The haemostatic changes after injury are similar
to those after surgery, and thus it seems logical to
test the hypothesis that antifibrinolytic agents may
reduce blood loss, the need for transfusion and
mortality following trauma. However, to date there
has been only one small randomized controlled trial
(70 randomized patients, drug versus placebo:
0 versus 3 deaths) of the effect of antifibrinolytic
agents in major trauma9. As a result, there is
insufficient evidence to either support or refute a
clinically important treatment effect.
It is important to investigate a simple and widely
practicable treatment that might reduce blood loss
following trauma, for worldwide it might prevent
thousands of premature trauma deaths each year and
could reduce exposure to the risks of blood transfusion.
Blood is a scarce and expensive resource and major
concerns remain about the risk of transfusion-
transmitted infection. Indeed trauma is common in
parts of the world where the safety of blood transfusion
is not assured. A recent study in Uganda estimated
the population-attributable fraction of HIV acquisition
as a result of blood transfusion to be around 2 per cent,
although some estimates are much higher10,11. Only 43
per cent of the 191 WHO member states test blood
for HIV and hepatitis C and B viruses. Every year,
unsafe transfusion and injection practices are estimated
to account for 8-16 million hepatitis B infections, 2.3-
4.7 million hepatitis C infections and 80,000-160,000
HIV infections12.
A large randomized trial is therefore needed of
the use of a simple, inexpensive, widely practicable
antifibrinolytic treatment such as tranexamic acid
(aprotinin is considerably more expensive and is a
bovine product with consequent risk of allergic
reaction and hypothetically transmission of disease).
The trial population should comprise a wide range of
trauma patients, who when they reach hospital are
thought to be at risk of major haemorrhage that could
significantly affect their chances of survival. To this
end a large international, placebo controlled trial of
the effects of the early administration of the
antifibrinolytic agent tranexamic acid on death,
vascular events and transfusion requirements has been
designed13. Known as CRASH 2 (Clinical
Randomisation of Antifibrinolytic in Significant
Haemorrhage), this trial will be one of the largest
clinical trials in trauma ever conducted.
The trial aims to recruit 20,000 patients worldwide
and recruitment began in May 2005.  Recruitment is
expected to be completed in December 2009. To date,
over 3,500 patients have been recruited at over 80
participating hospitals. Recruitment in India is
particularly strong with over 500 patients recruited to
date. However, in order to reach the recruitment target
of 20,000 patients many more hospitals in India are
required. The Data Monitoring Committee convened
on August 2006 and reviewed data on more than 1800
randomized patients. The Committee commended the
collaborators on the excellent recruitment and it was
the view of the committee that “the interim analyses
provided no reason for modifying the CRASH-2
protocol on the basis of safety or efficacy.”
The CRASH-2 trial collaborators have made an
outstanding contribution by ensuring that the trial is
already the largest clinical trial in traumatic
haemorrhage. However, to achieve the CRASH-2
trial objectives, many more participating hospitals
are needed. We invite doctors in India to join this
international collaboration and in this way help to
build the evidence base for trauma care.
Please visit the trial website for further
information about how to joins: http:/
www.crash2.lshtm.ac.uk.
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